Group 1: Future Industries with High Prosperity - The article emphasizes the importance of identifying industries that can maintain independent high prosperity despite geopolitical tensions and rising oil prices, suggesting that these sectors will have advantageous positioning in investment portfolios [1] - Current focus areas include optical communication and AI-related sectors, which are expected to remain prosperous, although they are somewhat linked to the fluctuations caused by the Middle East conflict [1] - Recommendations include investing in energy storage chains (inverters/lithium battery chains) and domestic AIDC chains, particularly those related to ByteDance, as they are on an upward trend and less affected by oil price changes [1] Group 2: Basic Medicine Directory Update - The National Health Commission and other departments are set to revise the National Essential Medicine Directory, with updates expected every three years, marking a shift towards a more predictable and regular update process [2] - The revision aims to promote both traditional Chinese medicine and chemical drugs equally, ensuring that pediatric medicines are included, which opens up opportunities for pediatric traditional Chinese medicine [2] - The implementation of the "986" policy, which mandates specific ratios for essential medicine distribution in public hospitals, is expected to be more strictly enforced, facilitating the penetration and volume growth of newly included products in various medical institutions [2] Group 3: Pharmaceutical Sector Insights - The pharmaceutical and biotechnology sectors are highlighted for their defensive characteristics, making them attractive for investment in the current external environment [3] - The article notes that segments within traditional Chinese medicine with strong performance and good chip structure are likely to exhibit significant elasticity [3] - The domestic demand-driven policy direction may lead to a turning point for companies related to pharmaceutical domestic demand [3]

Investment Rating - The industry rating is "Outperform the Market" [7] Core Insights - The report highlights that the National Health Commission has revised the management measures for the National Essential Medicines List, indicating that a new list will be released soon, which is expected to boost the volume of newly included products [4][18]. - The report suggests that the Chinese medicine sector is currently undervalued and underrepresented, with potential for a turning point due to policy catalysts, falling raw material prices, and inventory clearance [4][20]. - The report emphasizes that the pharmaceutical sector has been under pressure, with the CITIC Pharmaceutical Index down 2.9% for the week and 2.7% year-to-date, underperforming the CSI 300 Index [3][26]. Summary by Sections Market Review - The CITIC Pharmaceutical Index fell by 2.9% from March 16 to March 20, 2026, underperforming the CSI 300 Index by 0.8 percentage points, ranking 10th among CITIC's primary industry classifications [3][26]. - The top five performing stocks during this period were *ST Jingfeng (+27.7%), Sanofi (+23.1%), Jieda Biological (+15.6%), Jiuan Medical (+12.7%), and Xinlitai (+10.9%) [3][44]. Policy and Market Opportunities - The upcoming revision of the essential medicines list is expected to clarify the implementation of the "986" policy, which mandates that a certain percentage of essential medicines be stocked in various healthcare institutions [20][24]. - The report recommends focusing on leading state-owned enterprises and brand-name Chinese medicine companies, as well as potential opportunities in the essential medicines list [4][20]. Investment Strategy - The report outlines a strategy for 2026, focusing on three main areas: innovative drugs, medical devices, and companies benefiting from domestic demand [5][4]. - Suggested stocks for investment include Kangfang Biotech, Innovent Biologics, WuXi AppTec, and Sanli Pharmaceutical [5][14]. Performance Metrics - The overall valuation of the pharmaceutical sector as of March 20, 2026, is 27.91, with a relative valuation premium of 2.93% compared to the broader A-share market [34][41]. - The total trading volume for the pharmaceutical sector during the week was 417.38 billion yuan, accounting for 3.8% of the total A-share trading volume [41][44].

Group 1: Product Pricing and Stability - The core products' pricing system remains stable, with no expected price drops for the Wuling series and Bailing series, which are key products in the national medical insurance system [1][2] - The Bailing tablets and capsules have been selected for the national Chinese medicine procurement alliance, with the procurement period lasting until the end of 2027, ensuring price stability during this time [2] Group 2: Sales Channels and Strategies - The sales distribution is approximately 90% from hospital channels and 10% from external channels, with a strategy to deepen hospital penetration and expand external sales [3] - The company aims to leverage its advantages in national basic medicine and procurement selections to enhance coverage in hospitals, particularly in county-level medical communities [3] Group 3: Market Position and Competition - The multi-micro asset group products are covered in over 20 provinces, with a strong market presence in pediatric and maternal-child hospitals, and the brand "Litianwei®" has gained recognition [4] - Wuling capsules hold the top market share in the traditional Chinese medicine neurological field in urban and county public hospitals, with main competitors including Bailemi capsules and Zao Ren An Shen granules [6] Group 4: Organizational Structure - The marketing headquarters includes various departments such as self-operated hospital divisions, OTC business, and government affairs, employing a combined sales model of self-operation and agency [7] Group 5: Industry Environment and Policy Impact - The year 2026 marks the beginning of the "14th Five-Year Plan," with ongoing policy benefits for the traditional Chinese medicine industry, creating structural opportunities in both hospital and external markets [8] - Recent government guidelines aim to enhance grassroots medical services, providing market opportunities for the company to expand its existing four basic medicine varieties [8]

Investment Rating - The report maintains a "Strong Buy" rating for the company, indicating an expected stock performance that will exceed the market by more than 20% within the next six months [12]. Core Views - The company is experiencing short-term performance pressure due to multiple factors, including slower-than-expected execution of traditional Chinese medicine procurement and ongoing healthcare cost control policies. This has impacted both existing and new business segments [7][8]. - The company is undergoing a critical internal transformation, focusing on enhancing brand and market development while leveraging resources from its major shareholder, China Resources Sanjiu, to support retail business growth [7][8]. - The introduction of a new basic drug directory management approach is expected to benefit the company, particularly for products with strong evidence in clinical efficacy [7][8]. Financial Summary - The company forecasts a revenue of 6.577 billion yuan for 2025, representing a year-over-year decline of 21.72%. The expected net profit attributable to shareholders is 350 million yuan, down 46% year-over-year [3][8]. - Revenue projections for 2026 and 2027 are 6.916 billion yuan and 7.281 billion yuan, respectively, with expected growth rates of 5.2% and 5.3% [8]. - Key financial metrics include a projected gross margin of 38.8% for 2025 and a net margin of 5.3% [6][10]. Business Outlook - The company is positioned to recover growth as it completes its channel reform and adjusts its product offerings. The 777 series products and premium national medicine segments are anticipated to resume growth [8]. - The report emphasizes the importance of strategic investments in brand building and market expansion to enhance sales performance in the long term [7][8].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [1] Core Insights - The upcoming adjustment of the National Essential Medicines List (NEML) is expected to benefit traditional Chinese medicine (TCM) stocks, with a focus on companies like Zhaoli Pharmaceutical, Fangsheng Pharmaceutical, and Panlong Pharmaceutical [2][17][22] - The report ranks sub-sectors in the following order of preference: innovative drugs > research services > CXO > TCM > medical devices > pharmacies [2][11] - Historical data indicates that products included in the NEML tend to experience significant sales growth, as seen with Zhaoli Pharmaceutical's Wuling Capsule, which saw sales growth rates increase from -12.82% in 2017 to 32.52% in 2021 after being included in the NEML [19][22] Summary by Sections Investment Highlights - The report suggests focusing on TCM stocks due to the imminent NEML adjustments, recommending Zhaoli Pharmaceutical, Fangsheng Pharmaceutical, and Panlong Pharmaceutical [2][17] - The report emphasizes the importance of the NEML adjustments, which have not occurred in eight years, and the potential for TCM products to gain market share [22] R&D Progress and Company Dynamics - Recent approvals and submissions include Sanofi's Dupilumab for new indications and GSK's hepatitis B therapy application in Japan [5] - The report highlights various companies across different therapeutic areas, including innovative drugs, ADCs, and small nucleic acids, suggesting a diversified investment approach [13][22] Market Performance - The A-share pharmaceutical index has shown a year-to-date increase of 3.0%, with notable performances from specific stocks such as Aidi Te (+36.9%) and Wanze Shares (+27.5%) [10] - The report notes that the medical sector has seen varied performance, with biopharmaceuticals and medical devices showing positive trends, while chemical pharmaceuticals and medical services have faced declines [10]

Investment Rating - The industry rating is maintained at "Overweight" [3] Core Insights - The Chinese medicine sector is expected to undergo a rapid transformation over the next five years, driven by policy changes and innovation [3][8] - The market performance of the Chinese medicine sector has been moderate, with a recent increase of 0.73% in the Chinese medicine II index, indicating a stable position among pharmaceutical sub-sectors [5][19] - Key drivers for the hospital Chinese medicine market include the adjustment of the essential medicine catalog and innovation-driven growth, which are anticipated to create significant opportunities [9] Market Performance - The Chinese medicine II index closed at 6376.45 points, with a 0.73% increase over the past week [5][19] - The relative performance over the last 12 months shows a decline of 18% compared to the CSI 300 index [5] Valuation - The price-to-earnings (PE) ratio for the Chinese medicine sector is 27X, down by 0.49X from the previous week, while the price-to-book (PB) ratio is 2.27X, also showing a slight decrease [7] - The PE ratio is positioned at the 28.30% percentile since 2013, and the PB ratio is at the 5.37% percentile, indicating a relatively favorable valuation environment [7] Investment Recommendations - The report suggests focusing on companies with strong evidence of clinical efficacy, innovative research capabilities, and quality control advantages, particularly in the context of the essential medicine catalog and innovation-driven growth [8][9] - Recommended companies include Yiling Pharmaceutical and Zuoli Pharmaceutical, with a suggestion to monitor the recovery of downstream demand for consumer-oriented Chinese medicine [9]

Investment Rating - The industry investment rating is maintained at "Overweight" [2] Core Insights - The year 2025 is characterized by the Chinese medicine industry experiencing a bottoming out phase amid multiple pressures, with both performance and valuation reaching historical lows. The industry faces challenges from demand decline, high base effects, and inventory destocking. Policy impacts include centralized procurement and price governance, which disturb market expectations, leading to a downward shift in price levels and accelerated industry differentiation. The market performance shows that valuations are at historical lows, with institutional allocation ratios dropping to a low point. The year 2026 will see several critical validation points, focusing on policy and inventory cycles as core variables [4][5][9] Summary by Sections 1. Industry Performance in 2025 - The Chinese medicine industry is expected to face a downturn in 2025, with performance under pressure from demand decline, high base effects, and inventory issues. The industry’s revenue for the first three quarters of 2025 is reported at CNY 259.07 billion, a year-on-year decrease of 4.08%, while net profit is CNY 29.499 billion, down 1.46% [15][16][18] 2. Policy Variables - The year 2026 will see significant policy impacts on the Chinese medicine industry, focusing on four dimensions: top-level design for high-quality development, supply-side optimization, normalization of centralized procurement, and adjustments to the essential drug catalog. The release of the "Implementation Plan for High-Quality Development of Traditional Chinese Medicine Industry (2026-2030)" marks a shift from scale expansion to quality and efficiency improvement, which is expected to enhance the overall competitiveness and sustainability of the industry [5][6][9] 3. Inventory Cycle - After a deep adjustment in 2024-2025, the inventory turnover levels in the Chinese medicine industry are expected to improve gradually. The retail environment is showing signs of recovery, and the adjustment of the essential drug catalog may bring additional demand from hospital channels. The industry is anticipated to gradually clear inventory in 2026, with companies that have high inventory turnover rates and strong brand power likely to recover first [8][9] 4. Investment Strategy - The investment strategy for 2026 emphasizes seeking certainty in alpha through structural differentiation based on core competitiveness. The report recommends focusing on companies with evidence-based medicine, R&D innovation capabilities, quality control advantages, and brand moats. In the hospital market, attention should be paid to the catalytic effects of the essential drug catalog and innovation-driven breakthroughs, while in the external market, recovery driven by inventory stabilization and domestic demand should be monitored [9][10]

Core Viewpoint - The new management measures for the National Essential Medicines List emphasize the selection of drugs based on their clinical value and establish a rigid adjustment cycle of no more than three years for the list [1][2][3] Group 1: Essential Medicines List Management - The revised management measures state that the essential medicines should meet basic medical needs, be suitable for current national conditions, and ensure supply and affordability [2] - The previous version of the management measures had not been updated since 2018, with the current list containing 685 drug varieties [2] - The new measures highlight the importance of timely adjustments to the essential medicines list, with a focus on dynamic management and regular evaluations [2][3] Group 2: Clinical Value and Drug Selection - The new management measures stress the importance of clinical value in drug selection, aiming to include more innovative drugs that meet clinical needs [3][5] - The selection process for the essential medicines list does not accept applications from companies; instead, it is determined by a coordination mechanism involving 11 departments [3][5] Group 3: Coordination with Other Policies - The revised measures aim to improve coordination with other healthcare policies, including medical insurance and centralized procurement [6][8] - The management measures have removed the requirement for all grassroots medical institutions to exclusively use essential medicines, allowing for more flexibility in drug selection [7] - Future adjustments to the essential medicines list will consider various factors, including public health needs, disease spectrum changes, and drug safety monitoring [9]

Group 1 - The core viewpoint of the news is that traditional Chinese medicine (TCM) stocks are experiencing an upward trend, with Da Ren Tang rising over 5%, which in turn boosts the performance of various TCM ETFs [1] - Da Ren Tang announced a cash dividend distribution of 2.45 yuan per share, totaling approximately 1.886 billion yuan, based on a total share capital of 770,094,356 shares [2] - The TCM ETFs closely track the CSI Traditional Chinese Medicine Index, with major weighted stocks including Yunnan Baiyao, Pian Zai Huang, Dong E E Jiao, Tong Ren Tang, and others [1][2] Group 2 - New regulations are reshaping the TCM landscape, with the implementation of the Drug Administration Law and specific regulations for TCM registration, emphasizing a review system that combines traditional theory, human experience, and clinical data [3] - Century Securities believes that the TCM industry is likely to undergo a reshuffle due to recent policies promoting compliance and innovation, favoring leading enterprises with a strong reserve of classic formulas [3] - Xiangcai Securities indicates that the TCM material market is expected to transition towards scale, standardization, and branding, following a period of chaotic expansion [4] Group 3 - Three main investment themes are identified: price governance, consumption recovery, and state-owned enterprise reform [5][6] - Price governance focuses on the impact of price reductions through centralized procurement and insurance negotiations, with a recommendation to pay attention to unique products and companies with strong R&D capabilities [5] - The consumption recovery theme highlights the potential for increased sales of consumer TCM products due to macroeconomic recovery and an aging population, benefiting companies with brand and product advantages [6]

Summary of Kangyuan Pharmaceutical Conference Call Company Overview - **Company**: Kangyuan Pharmaceutical - **Industry**: Pharmaceutical, specifically focusing on traditional Chinese medicine and innovative drugs Key Points Financial Performance - In 2025, Kangyuan Pharmaceutical experienced a decline in revenue and sales profit, with net profit decreasing by 30% compared to the previous year. However, the fourth quarter saw significant growth in flu-related products and other major products, which helped narrow the overall decline in revenue and profit for the year [4][2]. Organizational Changes - The company has restructured its organization by establishing a Cardiovascular Division and a Sunshine Division. This aims to focus on the development of core products like Ginkgo and Tianshu, as well as new retail OTC channels, to promote a diverse portfolio of innovative drugs by 2026 [2][4]. Product Pipeline and Market Strategy - Kangyuan Pharmaceutical anticipates that 5 to 6 key products will likely enter the essential drug list, primarily in pediatrics and cardiovascular fields, which will help the company quickly capture market share in grassroots markets [2][5][6]. - The company is actively addressing the impact of DRG/DIP payment policies by enhancing academic promotion and advancing innovative product combinations to stabilize revenue and profit [2][13]. Clinical Trials and Innovations - The company is making progress in clinical trials for its three-target and two-target diabetes drugs, expecting to complete Phase II trials and read data by May 2026, indicating strong market potential [2][11]. - The first biological innovative drug, ZHONGXING 1,305 eye drops, is expected to be launched in 2027, with a concentrated period of innovative drug launches planned for 2028-2029 [3][15]. Regulatory Environment - The adjustment of the essential drug list policy emphasizes prioritizing innovative drugs and strengthening evidence-based medicine research. Kangyuan Pharmaceutical believes it has a competitive advantage in this area due to its commitment to clinically valuable innovation [5][9]. Market Outlook - The company aims for a rebound in 2026 after a challenging 2025, with a focus on core products and a sales strategy to achieve growth and address investor concerns [8][17]. - Kangyuan Pharmaceutical is also preparing for the commercialization of new drugs, with plans to increase R&D funding and potentially consider strategic partnerships to meet future funding needs [15]. Challenges and Opportunities - The new regulations for traditional Chinese medicine are seen as a positive signal for industry development, although they may pose risks for smaller companies. Kangyuan Pharmaceutical views this as an opportunity to increase industry concentration [9][10]. Future Expectations - Despite the setbacks in 2025, Kangyuan Pharmaceutical plans to leverage its strengths and enhance collaboration and R&D investments to achieve better results in 2026 [17]. This summary encapsulates the key insights from the conference call, highlighting the company's strategic direction, product pipeline, and market outlook.